In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 4.16 below Monte Rosa Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 41 other companies have achieved higher Quick Ratio than Monte Rosa Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 554, from total ranking in the second quarter 2026 at 564.

Explain Quick Ratio?
How much Cash & cash equivalents GLUE�s has?
What are GLUE�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GLUE/financial-strength

https://api.csimarket.com/api/v1/companies/GLUE/fundamentals

https://api.csimarket.com/api/v1/companies/GLUE/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

GLUE Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	9.98 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	47.66 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	4.16	Subscribe	Subscribe	Subscribe	Subscribe
GLUE's Total Ranking	# 554	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	0.34 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-49.85 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 42
Healthcare Sector	# 198
Overall Market	# 554

Quick Ratio Statistics
High	Average	Low
33.09	11.03	2.12
(Jun 30 2021)		(Dec 31 2024)

Financial Statements
Monte Rosa Therapeutics Inc 's Current Liabilities	$ 139 Millions	Visit GLUE's Balance sheet
Monte Rosa Therapeutics Inc 's Cash & cash equivalent	$ 578 Millions	Visit GLUE's Balance sheet
Source of GLUE's Sales		Visit GLUE's Sales by Geography

Cumulative Monte Rosa Therapeutics Inc 's Quick Ratio

GLUE's Quick Ratio for the trailling 12 Months

GLUE Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	25 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	100.94 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	5.5	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3749	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	2.57 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	7.21 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to GLUE Financial Strength Comparisons >> Go to Compare GLUE Quick Ratio to its Competitors

On the trailing twelve months basis GLUE Cash & cash equivalent soared by 47.66 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Monte Rosa Therapeutics Inc 's Quick Ratio to 5.5, above GLUE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 139 other companies have achieved higher Quick Ratio than Monte Rosa Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2732 to 3749.

Explain Quick Ratio?
How much Cash & cash equivalents GLUE�s has?
What are GLUE�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 140
Healthcare Sector	# 874
Within the Market	# 3749

trailing twelve months Quick Ratio Statistics
High	Average	Low
22.95	5.49	1.42
(Mar 31 2022)		(Dec 31 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Kalaris Therapeutics Inc	9.73	$ 82.856 Millions	$ 8.514 Millions
Zura Bio Limited	9.22	$ 187.652 Millions	$ 20.349 Millions
Protara Therapeutics Inc	8.83	$ 127.050 Millions	$ 14.391 Millions
Immunovant Inc	6.94	$ 722.274 Millions	$ 104.022 Millions
Repligen Corp	6.87	$ 862.979 Millions	$ 125.686 Millions
Compass Therapeutics Inc	6.69	$ 163.058 Millions	$ 24.368 Millions
Black Diamond Therapeutics Inc	6.62	$ 102.030 Millions	$ 15.405 Millions
Krystal Biotech Inc	6.45	$ 916.484 Millions	$ 142.144 Millions
Voyager Therapeutics Inc	6.35	$ 106.806 Millions	$ 16.813 Millions
Cabaletta Bio Inc	6.33	$ 299.383 Millions	$ 47.332 Millions
Cognition Therapeutics inc	6.00	$ 30.758 Millions	$ 5.128 Millions
Replimune Group Inc	5.57	$ 307.833 Millions	$ 55.271 Millions
Denali Therapeutics Inc	5.42	$ 516.196 Millions	$ 95.258 Millions
In8bio Inc	5.32	$ 13.973 Millions	$ 2.628 Millions
Scholar Rock Holding Corp	5.16	$ 413.599 Millions	$ 80.124 Millions
Revolution Medicines Inc	4.81	$ 3,651.385 Millions	$ 758.773 Millions
Caribou Biosciences Inc	4.71	$ 94.881 Millions	$ 20.144 Millions
Recursion Pharmaceuticals Inc	4.47	$ 549.853 Millions	$ 122.918 Millions
Ginkgo Bioworks Holdings Inc	4.33	$ 285.361 Millions	$ 65.849 Millions
Fate Therapeutics Inc	4.26	$ 139.132 Millions	$ 32.691 Millions
Kymera Therapeutics Inc	4.16	$ 373.374 Millions	$ 89.723 Millions
Monte Rosa Therapeutics Inc	4.16	$ 577.726 Millions	$ 139.022 Millions
Vir Biotechnology Inc	4.08	$ 454.635 Millions	$ 111.332 Millions
Moderna Inc	3.93	$ 7,976.000 Millions	$ 2,028.000 Millions
Immunocore Holdings Plc	3.93	$ 901.298 Millions	$ 229.619 Millions
Alector Inc	3.92	$ 138.697 Millions	$ 35.415 Millions
Dbv Technologies S a	3.89	$ 165.700 Millions	$ 42.600 Millions
Regenxbio Inc	3.71	$ 250.976 Millions	$ 67.684 Millions
Tenaya Therapeutics Inc	3.55	$ 66.797 Millions	$ 18.804 Millions
Alpha Cognition Inc.	3.41	$ 37.802 Millions	$ 11.093 Millions

Date modified: 2026-11-08T19:24:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.